Comparative Pharmacology
Head-to-head clinical analysis: PREMPRO PREMARIN CYCRIN versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMPRO PREMARIN CYCRIN versus STILBESTROL.
PREMPRO (PREMARIN;CYCRIN) vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREMPRO combines conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN). Estrogens bind to estrogen receptors (ERα and ERβ), activating gene transcription involved in cell growth, differentiation, and function. Progestins like medroxyprogesterone acetate bind to progesterone receptors, antagonizing estrogen-induced endometrial proliferation and reducing risk of endometrial hyperplasia.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
One tablet (0.625 mg conjugated estrogens/2.5 mg medroxyprogesterone acetate or 0.625 mg/5 mg) orally once daily.
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Conjugated estrogens: 10-24 hours (terminal); medroxyprogesterone acetate: 12-17 hours. Clinical context: steady-state reached after 5-7 days.
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Conjugated estrogens and medroxyprogesterone acetate are primarily excreted in urine as glucuronide and sulfate conjugates; about 10% excreted in feces via bile.
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen/Progestin Combination
Estrogen